{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-035657","form_type":"8-K","ticker":"IONS","cik":"0000874015","company_name":"IONIS PHARMACEUTICALS INC","filed_at":"2026-09-04T10:01:59+00:00","discovered_at":"2026-09-04T10:05:00.274416+00:00","generated_at":"2026-09-04T10:05:03.504189+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"FDA approves Ionis' ZANVASTRO (zilganersen) for Alexander disease","bullets":["ZANVASTRO is first and only disease-modifying treatment for AxD; 50 mg intrathecal quarterly.","Pivotal study met primary endpoint: gait speed stabilization at Week 61 (LS mean diff 33.3%, p=0.041).","FDA granted Rare Pediatric Disease Priority Review Voucher with approval.","Recordati holds ex-U.S. rights; EU/Japan regulatory submissions expected in 2027.","ZANVASTRO available in U.S. in coming weeks; Ionis' first independent neurology launch."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-035657","json":"https://secwatch.observer/filing/0001140361-26-035657.json","markdown":"https://secwatch.observer/filing/0001140361-26-035657.md","text":"https://secwatch.observer/filing/0001140361-26-035657.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874015/000114036126035657/0001140361-26-035657-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874015/000114036126035657/ef20081649_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-04T10:05:03.504189+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}